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Peripheral nerve injury in adults often leads to permanent functional loss with or without 
pain.  Traumatic injury or surgery, metabolic injury (diabetic neuropathy), and drug toxicity 
can lead to neuropathies and all negatively impact the quality of life1-8.  Damage to the 
nervous system is often permanent since neurons in the brain and periphery are post-mitotic 
and have limited regenerative capacity.  Nerve repair involves axon regeneration, a complex 
and incompletely understood process with repair potential declining with age9-15.   
 The research and design discussed involves the induction of endogenous repair 
mechanisms of the peripheral nerve using embryonic stem cells, alginate hydrogel, and the 
guided support of a biomaterial scaffold composed of PGS.  Three different populations of 
cells are discussed: human embryonic stem cells, neural progenitor cells derived from human 
embryonic stem cells16, and primary rat bone marrow stromal cells.  This study was 
innovative in that it was the first attempt for use of an elastomeric biomaterial scaffold in an 
injury model for the purpose of clinical application.  This research is significant as it has direct 
clinical relevance in that it incorporates both functional and neuropathic recovery of patients affected 









Physiology of Peripheral Nerve Trauma  
The physiological response to a peripheral nerve injury is the sprouting of neurites from 
the proximal stump of the damaged nerve, while the distal nerve undergoes Wallerian 
degeneration, a programmed process that involves the degradation of the myelin sheath, 
segmentation of the axon, ‘dedifferentiation’ of Schwann cells to non-myelinating cells, and 
infiltration of macrophages17-21.  Specifically this change occurs via an influx of calcium ions 
through specific channels that activate proteases which subsequently degrade the axolemma 
and axoplasm of the distal nerve19, 22-24.  Although the regenerating proximal axon must cross 
to the injured or severed distal nerve, there is no reconnection of the tissues, but rather new 
growth through an optimized track for reinnervation of the distal tissue25, 26.  In cases where 
the axon and dendrites sprout laterally innervating new tissues, the result is an increase of 
neuropathic pain thus it is crucial to promote nerve guidance in the correct path as soon as 
possible17, 18, 24, 25, 27.  During this axonal migration, the Schwann cells begin to dedifferentiate, 
also taking on a different phenotype and role incompletely understood17, 18, 24. 
One of the changes in the Schwann cells during this process is the upregulation of 
Epo and Epo receptors on their surface, providing a target for Epo signaling which may play 
a role in subsequent nerve regeneration21.  Epo is a hematopoietic cytokine that has been 
shown to be neuroprotective in ischemia28 and after crush injuries29, possibly acting as an 
antagonist to inflammatory cytokines30.  Epo binds to EpoR which triggers dimerization and 
stimulation of Jak2, a Janus kinase, which in turn activates extracellular signal-regulated 




the hypoxic upregulation of Epo and cell proliferation lies in that proliferated erythrocytes 
can systemically deliver more oxygen reaching the hypoxic site, thus downregulating Epo.  
Epo is known to promote the neurotrophic effects of proliferation and 
differentiation31 as well as reduce neuropathic pain resulting from nerve injury29, 32.  As the 
Schwann cells dedifferentiate, no longer attached to the axon, they begin to proliferate and 
form the Bands of Büngner, which provide support and guidance from the proximal nerve 
stump to the distal stump19, 20.  Another change that the Schwann cells exhibit is the down-
regulation of myelin-associated genes, and up-regulation of neurotrophic factors including 
NGF, BDNF, and GDNF as well as interleukin-6 and leukemia inhibitory factor which are 
both cytokines20.  Despite the upregulation of trophic factors and other means by which the 
nerve can self-repair, many cases are too severe for endogenous repair ultimately resulting in 
a loss of function as well as the addition of neuropathic pain.  Other causes of neuropathic 
pain are a result of misdirected axonal sprouting, organizational changes in central nuclei, 
and hyperinnervation; all phenomena associated with ‘successful’ regeneration25, 26, 33, 34. 
 
Characteristics of Neuropathic Pain 
Neuropathic pain is pain resulting from insult to the peripheral or central nervous 
system35 and affects approximately 1.8 million people in the United States36.  Neuropathic 
pain (as opposed to nociceptive pain) has a particular pattern including extreme reaction to 
non-noxious stimuli (allodynia) and hyperalgesia.  The aforementioned causes of peripheral 
nerve damage: physical trauma, metabolic injury, and drug toxicity all follow as causes for 
neuropathies1-8; however the mechanisms for neuropathic pain are incompletely understood.  
The physiological response to intense or damaging noxious stimuli is the triggering of high-




different from spontaneous pain, or pain elicited from non-noxious stimuli without 
triggering the sensory neurons, characteristics of neuropathic pain – pathological pain.   
 Several tests have been established to provide quantitative measures with neuropathic 
pain, focusing on the allodynic and hyperalgesic effects of the neuropathies.  One model that 
has aided this study significantly is the chronic constriction injury model (CCI) introduced by 
Bennett and Xie38.  This model uses 4 sutures to constrict the sciatic nerve, which ultimately 
induces pain consistent with human patients exhibiting neuropathic pain.  Quantitative 
measures have been applied to mechanical allodynia using Von Frey filaments, weighted 
filaments dropped on the paws of the test subjects, and hyperalgesia using hot and cold 
plates measuring the latency of paw withdrawal.   
 Treatment of neuropathic pain is often limited and unsuccessful.  Patients with 
neuropathic pain are typically insensitive to opioids and other non-steroidal anti-
inflammatory drugs37.  This pain is typically treated pharmacologically with tricyclic 
antidepressants, serotonin and norepinephrine uptake inhibitors, and anti-epileptics; 
however there is limited efficacy and often undesirable side-effects with such treatments37, 39, 
40.  Recent studies have also shown that exogenous Epo can be used to reduce neuropathic 
pain by regulating pain producing cytokines29. 
 The response to pain is in conjunction with an inflammatory response introducing 
bradykinins, TNFα, endothelins, hydrogen ions, substance P, IL-1β, NGF, prostaglandins, 
histamine, and ATP, as well as an accumulation of sodium channels increasing the number 
of spontaneous ectopic discharges29, 39-41.  Endothelin-1 is suspect to cause neuropathic pain 
as well as TNF-α41-43.  One type of Endothelin receptor, ETA, has been shown to participate 
in the inflammatory reaction, triggering an algesic pathway.  Contrarily, ETB shows the 




opioid receptors on nociceptors42, 44. Another suspect to neuropathic pain is the 
inappropriate reinnervation following nerve injury; the sprouting of new nerves with new 
undirected targets26.   
 Because of the poor understanding of neuropathic pain, there are very few treatments 
for it, and those which are available have relatively low efficacy.  Neuropathic pain is one 
inherent problem with neural damage, and despite its poor understanding, it is critical to 
regulate and reduce in the clinical setting.  Due to the nature of neuropathic pain and the 
pathologies it is associated with, neuropathies and neuropathic pain increases with the age of 
the patient.  Aging not only affects the pain, however, it also affects the overall regenerative 
response on both the gross level as well as the cellular level.   
 
Aging and Nerve Regeneration 
Age-specific morbidity rates for pain increase per decade of life, with a prevalence as 
high as 67-80% among the elderly45-47.  Prevalence of neuropathic pain follows this trend, 
also increasing with advancement in age, with decreasing potential for full recovery10-13, 15.  
One factor that induces nerve damage with elevated effects in age is insult from reactive 
oxygen species, which play a role in abnormalities in nociceptive processing48, 49.  There is an 
excess of generated ROS in peripheral nerve injuries, and to further exacerbate this problem, 
the enzymatic activity and mRNA expression of the antioxidant SOD and catalase decrease 
as a function of age48, 50, 51.   Despite the increase in occurrence across age groups, the 
magnitude of neuropathic pain symptoms is not significantly different; however the rate of 
recovery is significantly reduced in older subjects52, 53.  The age-related decrements in 
endogenous antioxidant defense severely predispose cells for free-radical damage, thus 




 In the cell, there are three primary mechanisms by which the oxidative stress is 
ameliorated.  Catalase, found in the peroxisomes, superoxide dismutatases found in the 
cytosol and mitochondria, and GPx1 found throughout the cell.  There are two predominant 
types of SOD in humans, Sod1 and Sod2, the cytosolic and mitochondrial SODs 
respectively.   The SODs both catalyze the reaction changing intracellular superoxide ions 
into oxygen and peroxide, while catalase and GPx1 both breakdown the peroxide molecule 
into water.  With compromised machinery in these enzymes, there is great potential for 
oxidative damage by the accumulating superoxides and free oxygen radicals.  This is linked 
to aging by the aforementioned decreases in mRNA expression with age, thus demonstrating 
the criticality of irreparable cells depending on these mechanisms for lifelong survival. 
 
Current Therapies for Peripheral Nerve Damage 
The current therapies for peripheral nerve repair are limited; the most successful 
procedure in nerve repair is autologous nerve grafting which requires removal of a healthy 
nerve from elsewhere in the body and generally provides incomplete recovery.  Short gap 
nerve transection does not require the graft of additional nerve tissue; however, one 
shortcoming in both procedures is damage from sutures as well as incomplete recovery of 
the distal nerve.  Some advances have been made improving upon this procedure including 
the use of fibrin glue in lieu of nylon sutures26, 54-59.  Despite the success of fibrin as a suture 
material, the efficacy of the graft itself is limited. 
 Many engineering approaches to address the limited efficacy of the autograft have 
provided new means for peripheral nerve repair.  Biomaterials have been used to directly 
affect the nerve regeneration or as a scaffold to support cells which affect regeneration.  The 




end of the lesioned nerve is inserted, encouraging/directing the nerves to path-find and fuse 
to its severed distal stump.  Different cell populations have also been used to implant with 
the scaffolds, but Schwann cells have been the primary focus as they are known to play a 
critical role in peripheral nerve regeneration.  Despite the many materials, cells, and 
modifications to these engineered approaches, none have significantly improved upon 
autologous grafting. 
 NGCs have been constructed from many different biomaterials, each with different 
physical and chemical characteristics.  Some of the most common materials used to 
construct NGCs have been poly[lactic-co-glycolic] acid60-64, poly[L-lactide-co-6-
caprolactone]65-67, poly[phosphoester]68, 69, poly[L-lactic] acid61, 70, 71, gelatin72-74, chitosan75-82, 
and several hydrogels (as nerve guidance materials rather than channels)83-98.  Aside from 
using different materials, some studies focused on the modification of existing material 
channels/scaffolds using growth factors (NGF, BDNF, FGF, GDNF)69, 71, 99, 100, surface 
modification (smooth vs. rough/micropatterned)69, 78, 83, 101-103, and implantation of Schwann 
cells62, 77, 87, 89, 94, 103-112.  As previously mentioned, despite these many modifications and 
promising enhancements, none of the engineered implants have significantly improved upon 
autologous nerve grafting60, 62, 68, 82, 83, 101, 102, 113.   
Failures of these attempts at improved nerve regeneration may be a result of a 
culmination of factors including undesirable immune response, inability of neurotrophic 
factors released from the proximal stump to reach the distal stump, lack of a defined matrix 
to support the regenerating nerve, inappropriate material characteristics, and in some cases 
the lack of Schwann cells in the immediate area64, 114, 115.  Geometry, porosity, 
biodegradability, biocompatibility, polymer chemistry, mechanical strength, and elasticity all 




cells, growth factors, and the extracellular matrix ultimately regulate the neuro-regenerative 
potential with hopes to optimize neural potential by inducing conditions mimicking the 
embryonic stage of nerve growth61.   
The scaffold provides the structure for the support cells as well as the nerve 
throughout regeneration, but predominantly during the initial phase, thus it is important that 
the material have an appropriate degradation rate, porosity to allow for cell recruitment as 
well as nutrient and gaseous exchange, mechanical strength to support the tissue, and 
elasticity similar to that of the tissue so as not to impede growth of the axon.  PGS is a 
unique material in that it is biocompatible, maintains its structural integrity throughout its 
biodegradation, and has elastomeric properties similar to that of nerve tissue116-120.  PGS 
implants gradually lost mechanical strength, about 8% per week, characteristic of surface 
erosion117.  The implants maintained geometry after implantation up to 35 days, and 
completely absorbed within 60 days117.  Additionally, the elastomeric property of PGS makes 
it ideal for work with nerve tissue, having a Young’s modulus of 0.5MPa117 compared to that 
of nerves: 0.45MPa119.  PGS scaffolds have also been shown to support several different cell 
types in vitro as well as Schwann cells in vivo78, 116-118.   
Although PGS use alone seems ideal for implantation, the density at which stem cells 
are seeded at has been shown to influence the cell fate in vivo121.  Similarly, the distribution 
within a hydrogel bead has been demonstrated to alter the capability for cells to migrate due 
to the ability to form a matrix network122.  These parameters cannot be controlled using the 
solid PGS scaffold alone, thus an alginate hydrogel will be employed to specifically control 
the cell density, distribution, and gel density to allow for migration.  These may prove to be 
crucial in limiting teratoma formation as well as allow for proper intercellular 




Use of Stem Cells in Nerve Regeneration 
Schwann cells have been the focus of support cells for many groups working with NGCs 
with limited success62, 77, 80, 83, 102, 103, 105, 106, 109, 111, 115, 123-125.  Adjuncts to the NGC have included 
stem cells in lieu of Schwann cells; particularly stem cells which have the potential to 
differentiate into both neural and support cells.  Human embryonic stem cells are one type 
of stem cells that are currently being used in these studies126-128.  hES cells are a pluripotent 
population of cells derived from the human embryo, capable of differentiating into the three 
separate germ layers, and have been demonstrated to differentiate into neuronal tissue in 
vitro129-132.  The aforementioned neural progenitor cells are derived from hES cells through a 
specific protocol.  Benefits in using NPCs rather than hES cells include problems with 
teratoma formation that is common with ES cells133-135.   However, the pluripotent nature of 
ES cells provides an opportunity for differentiation into the support cells needed for neural 
regeneration, as well as possibly providing an “embryonic phenotype” in the damaged 
region, creating the necessary environment for optimized axonal growth136.  Recent advances 
in understanding ES cell motor differentiation16, 43, 137-142 underscore the potential of these 
cells for therapeutic peripheral nerve regeneration, especially if the cells can be implanted on 






Development of a Working Scaffold 
 
 
This chapter discusses the methods and approaches taken in the development of a PGS 
scaffold that maintains mechanical integrity and supports cell growth and maintenance.  In 
order to optimize the scaffolds for further use in vivo, a thorough in vitro study of the 
behavior of cells on the biomaterial scaffold was essential.   
 The design of the initial scaffold used a microfabricated silicon mold as the template, 
while later designs used the principle of salt fusion to provide the scaffolds.  While the target 
for each of the technologies was slightly different, both did show potential for any future 
studies with this material.   
 
Using Microfabrication to Make a Delivery Network 
The design to be implemented was based on capillary branching patterns to ensure the 
appropriate diameter and bifurcation angle for physiological fluid properties.  In order to do 
this, the design was put in two dimensions using AutoCAD2005 software which was then 
sent in to a company who provided us with a glass mask with the negative of the design.  A 
coat of photoresist polymer was evenly spun onto the silicon plate to which the mask was to 
be transferred, and then exposed to UV light for the calculated time for the thickness of 
photoresist.   
Because the mask that was ordered was glass, rather than quartz, UV rays did not pass 
through, and the photoresist did not maintain the desirable pattern.  Furthermore, the 




machinery, making it very difficult to get training on.  With expenses related to keeping 
students in the clean room as well as the difficulty in getting training and improper mask, 
this technique was abandoned.  Furthermore, previous studies with this technique had 
demonstrated an uneven distribution of cells, with clusters only in the bifurcations120. 
 
Observing the Migratory Response of Cells  
One of the major premises behind this design was the ability for cells to migrate through 
the major clusters to fill in the gaps.  While microfabrication was abandoned, a series of 
simple “wound assays” (also known as scratch assays) were performed on PGS, glass, 
polystyrene, as well as laminin-coated PGS, glass, and polystyrene.  Furthermore, one set of 
each of these was left in ambient air conditions (20% oxygen) while the other group was 
maintained in 6% oxygen.   
Using a sterile 200µL pipetter tip, a scratch was made across each of the substrates.  For 
the next 36 hours, each plate was photographed under the microscope once every 3 hours to 
monitor the acceleration and rate of the migration.  We had hypothesized that the normoxic 
(6% O2) cells would migrate more rapidly than the ambient cells.   
Unfortunately, because of the exposure to ambient air pressure during the photography 
of the plates as well as inconsistencies in heat throughout the experiment, the many degrees 
at which the two sets varied continued to increase toward the end of the experiment, and 
furthermore, many of the plates started observing lifting of the cells, and rapid cell death 
from the movement of the fluid back and forth to the incubator to the extent that there were 




We discussed an automated design for both this and the aforementioned design, 
however, with the many setbacks these ideas were set aside and a new design was brought 
forth. 
 
Salt Fusion-Based Scaffolds for Nerve Regeneration 
This was a design based on an old technique in biomaterials, utilizing different 
solubilities of the biomaterial and salt147.  A salt, in our case Sodium chloride, fills a mold and 
is subjected to high humidity for a given amount of time allowing it to fuse together forming 
a complete negative mold for the polymer.  The polymer is poured over the dry salt structure 
and cured.  Once cured, water is used to dissolve the salt matrix, while the material remains 
in-tact.   
 The initial molds were a very simple design milling a trench in a strip of solid PTFE.  
The 12mm trench was designed to be both 5/32” wide and deep with an open surface for 
the salt to be poured in.   A second cut was made to fit a 1/16” PTFE coated needle to 
function as a lumen.  These dimensions were chosen as they are the size of the sciatic nerve 
in rat (1/16”), and a substantial but not intrusive thickness for cell seeding and maintenance.   
Up to seven of these trenches were made on a single block of PTFE.  After several 
cures, the PTFE started to warp causing a variation in the size of each scaffold depending on 
their position.  To rectify this problem I attempted to remove the salt scaffolds before curing 
the PGS at the higher temperature, but to no avail.  Another problem encountered was non-
uniform curing of the scaffolds.  The first attempt to fix these problems was to create the 
molds in aluminum however I wasn’t able to machine the aluminum such that it would 




 To overcome these problems as well as to get a fully circular shape, I designed the molds 
to have an upper and lower half which would be taken apart after the fusion of the salt.  
Following removal of the salt, the polymer would be applied to the salt templates on a flat 
piece of PTFE.  These would be cured suspended above the surface, also providing a more 
uniform curing.  In essence, this was the most effective method I attempted, however I was 
getting anywhere between a 25% and 75% yield at the end of the process.   
 
Scaffold Fabrication 
Poly (glycerol sebacate) (PGS) is synthesized as previously reported117.  Porous PGS 
scaffolds are prepared using a salt fusion method147 modified to accommodate the properties 
of PGS.  We used 1/16” polytetrafluoroethylene (PTFE) tubing covering 20 g needles (rat 
sciatic nerve is about 1mm in diameter66 ~ 19 g) embedded 1mm in the salt in a PTFE mold.  
The mold is incubated at 37ºC and 88% relative humidity for 150 minutes and then dried in 
a vacuum oven at M60ºC and 100mTorr overnight.  PGS dissolved in tetrahydrofuran 
(THF) is repeatedly added to the salt mold and allowed evaporate in a fume hood for 60 
minutes.  The mold is then cured in a vacuum oven at 150ºC and 100mTorr for 24 h.  After 
cooling, the PGS/salt molds are soaked in dH2O for 24 hours, exchanging the water every 4 
hours for the first 12 hours.  Scaffolds are then lyophilized and stored dry until use.  A series 
of ethanol washes is performed to remove any excess monomer prior to conditioning in 
medium.  While the inner diameter of the scaffolds is 18 g, the outer dimensions of the 
scaffolds will be varied to compensate for degradation and surface area for cell adhesion.   
 
Making the Scaffold Work In vitro 
While still working on making the scaffolds, the first set of In vitro experiments involved 




[Figure 1].  Although it was hypothesized that the N27 cells would proliferate over time, the 
contrary was found.  Because N27 cells had no impact on the future cells to be used in the 
study, these were no longer used, but instead primary bone marrow cells extracted from the 
femurs of rats.  Similarly because the nature of the 2D plate and 3D scaffold is so different, 
the cells were directly applied to scaffolds following removal and observed after 3 different 
time points [Figure 2].  Some problems with this second assay were that I was still using the 
initial scaffold design, so there was not uniformity in size or cross-linking density amongst 
the scaffolds.  Also, in calculating the values from the standard curve, when applied to the 
actual data obtained, the values for the latter two data were negative.  When repeated, the 
same results were obtained.   
 The next assay examined the difference between different surface modifications as well 
as different oxygen conditions.  Fibronectin and laminin were adsorbed to uniformly 
produced PGS scaffolds.  Scaffolds with the adsorbed proteins as well as without were 
seeded with primary bone marrow stromal cells obtained from rat.  Half of the scaffolds 
were placed in 6% oxygen while the rest were left in ambient conditions and cultured for 7 
days [Figure 3].  The results indicated that the laminin-coated scaffolds were not different 
from the null either oxygen condition, however, fibronectin was significantly higher than the 
null, but only in 6% oxygen.  With a similar trend, the control scaffold of unmodified PGS 
also had a significant difference between the 6% and 20% oxygen supporting the hypothesis 
that culture would be better supported at conditions representative of the in vivo 






The initial focus of this project was the implementation of a technology integrating cells 
and cell behavior with the biomaterial poly (glycerol sebacate).  The initial design utilized 
microfabrication to create a micro-array of capillaries through which a 3D network could be 
established.  The theory behind this technology is still sound, however the cost and 
resources available were limited at the time, and this was discontinued.  Furthermore, the 
previous attempts at gaining confluence throughout the network had not been successful.  
With the initial momentum of the project being migration of cells, the full design would 
have encompassed a full closed system to observe the behavior of the cells 24 hours a day 
while being fully automated to track different positions on a plate. 
 Keeping cell migration as the main task, the secondary steps involved simple wound 
assays which were assayed with different ligands as well as under different oxygen tensions. 
While working in low oxygen, I discovered it was nearly impossible to keep the plates from 
repeated spikes of exposure to 20% oxygen while taking photographs of them.  And due to 
the rate at which cells normally migrate, which is on the order of 24-36 hours, the only way 
that could circumvent these problems would be to either take pictures in a 6% oxygen 
chamber or to utilize a closed system that could maintain the low oxygen over the time 
period necessary.  This however, was not done as the total focus of the research was 
changed to something that could more readily use PGS. 
 The making of PGS scaffolds used a very simple process with several conditions that 
were easily controlled, however this proved not to be so simple in the producing of 
uniformly sized and cross-linked scaffolds.  The technologies that had been used in the lab 
prior to my experiments worked on a much larger scale, typically at least ten times larger.  




balancing the viscosity of the material with the capillary action of the salt scaffold, and even 
gravity.  Other problems arose because when a small break occurred on the larger scale, say a 
1mm break, they lost at best 1% of their scaffold, where a 1mm break cost the smaller 
scaffold 10%, and thus could no longer be used.  This was a problem with all designs, as 
when lifting the scaffold out of the PTFE mold was the first point of potential breakage as 
there was a vertical force applied by the thin needle in the lumen to the thin cylinder.  The 
second potential breaking point was in the removal of the needle, as the scaffold was placed 
back in the mold while the needle was removed axially.  The third breakage could occur 
when removing the ‘free’ salt scaffold from the mold again…often times the light tapping 
would cause breaks or the scaffold would break as it fell 10mm.   
 Because of all of these potential breaks in the scaffold prior to even adding PGS, there 
was a low yield.  On top of these problems, there was still no insurance that 100% of the 
samples were even going to be uniformly filled, as the PTFE is opaque and must be filled 
across both sides evenly.  Using a number of these molds with the exact amount of salt 
needed, I was eventually able to reach a yield of 75%.  
 Following the fabrication, the in vitro studies were designed to show the viability of the 
scaffolds with cells prior to the in vivo studies.  During the initial in vitro assay in which N27 
cells were grown on PGS-coated plates, the data shows a decline over time rather than 
proliferation [Figure 1].  This indicated that the PGS plate was toxic to the N27 cells.  This 
was attributed to monomers attached to the surface of the PGS which would be more 
thoroughly removed in future studies.   
 Instead of continuing with N27 cells, the experiment shifted to the use of primary bone 
marrow stromal cells extracted from rat femurs, isolated and then immediately put into the 




as extreme as seen with the N27 cells.  This assay was expanded to observe differences with 
oxygen tensions and ligands bound to the surface of the scaffold.  After 7 days in culture, the 
number of cells is extremely low compared to the number of cells that were seeded.  
Similarly the only samples that were significantly different in fluorescence from the null were 
the control and the fibronectin-coated.  While this assay did show there was a significant 
difference between 6% and 20% oxygen by ANOVA analysis, the low quantity of cells 
remained a problem for this experiment in general.  Despite these resulting low cell numbers 
on PGS scaffolds, there has been evidence that demonstrates that other cell types: Schwann 
cells116, fibroblasts117, 118, and even non-robust cardiomyocytes thrive on PGS scaffolds148, 149.  
These contrasting results demonstrate that it is not the properties of the PGS causing the cell 
death, but rather an interaction between the particular cells worked with in my experiments 
with the PGS.   
 The next step in the design was going to use alginate to encapsulate the cells and hold 
them within the scaffolds.  The final step in this project was the demonstration that alginate 
can be used to encapsulate and permeate the PGS scaffold.    
 




























Figure 2:   Arbitrary units of fluorescence representing marrow stromal cells cultured in PGS 
scaffolds over 5, 8, and 11 days.  Note:  units are arbitrary because in calculating the standard 
curve, days 8 and 11 would be negative numbers. 
 
 
Figure 3:  Cells per scaffold after 7 days of culture.  Null represents no cells grown on  







Experimental Methods for Potential Study 
 
This chapter discusses the experimental design following the procedures establishing a 
basis for future studies.  While these experiments were not fully or at all performed, a fully 
detailed experimental design was established after months of literature research and careful 
planning.  If this research is to be continued, this is the proposed design. 
 
Conditioning and Training Rats for Behavioral Testing 
In order to perform any form of behavioral analysis, a baseline must be obtained.  And 
in order to gain a regular baseline, the rats must be handled and accustomed to the setting 
where the experiments will be performed for several weeks prior to the experimentation.  
The tests the rats were being prepared for including controlled external stimuli applied to the 
paws of the rats, thus the rats are placed in a specialized cage in which stimuli could be 
applied from above and below.   
 In addition to the cage, the rats are also conditioned to walk freely on a large piece of 
white paper, and after initial conditioning, they have their paws dipped in ink to quantify 
their gait.  Ultimately, there are two general tests to be performed pre and post-surgery with 
the rats:  motor function assessment and functional recovery behavioral evaluation. 
 Motor function will be assessed by a basic motility test, the sciatic functional index 
(SFI)150, 151.  These indices are obtained by wetting the hind feet with 20% methyl blue and 
allowing them to walk freely in a paper-lined corridor and comparing the experimental 




spreading (TS), and intermediate toe spreading (IT) are measured to determine the SFI 
[Figure 4].  Rats will be analyzed for pain and functional recovery up to 60 days.  The 
sciatic functional index is determined by the following equation (where E and N are 























 Pain after injury will be assessed by quantitating thermal and mechanical hyperalgesia.  
Baseline paw withdrawal latency (PWL) to thermal stimulus will be used to assess the 
thermal sensitivity.  A radiant heat source directs a thermal stimulus to the paw, and a 
photoelectric cell detects light reflected off the paw so that when the paw is withdrawn from 
the heat source, the timer is stopped.  Mechanical allodynia will be evaluated by paw 
withdrawal response (PWR) to application of force using von Frey monofilaments.  The 
same tests will be performed at different time points following surgery to quantify the PWL 
and PWR in order to observe the functional recovery of the severed nerve.  A series of pre-
operative tests is used for comparison41.   
 All experiments using animals are conducted in compliance with NIH guidelines and 
institutional IACUC approval.  General anesthesia is induced with pentobarbital 40 mg/kg 
IP and supplemented with 2-4 mg/kg as needed to maintain anesthetic depth.  Both sciatic 
nerves are dissected free with microsurgical technique in strict aseptic conditions. A dorsal 
longitudinal skin incision is made slightly to the left of midline over the pelvic girdle. Slightly 
caudal and ventral to the left hip joint, a faint separation of muscle groups is visualized. A 10 




dissection. The sciatic nerve is visualized running parallel to the length of the femur. A 7-10 
mm length of the sciatic nerve, proximal to the sciatic trifurcation is carefully cleared from 
underlying tissue using blunt dissection153.  
The left sciatic nerve is either sutured with 4 sutures at ½ the length from the spinal 
cord, or transected at 2/3 its length from the spinal cord.  The right nerve serves as a 
control.  The scaffolds are placed along the site of injury, or in the case of removal each end 
of the transected nerve will be inserted into the lumen of the scaffold.  The nerve ends will 
be grafted using fibrin glue.  Approximately 5µL of fibrin glue will be applied and allowed to 
set for 5 minutes.  The surgical site is closed using surgical clips, and rats will be allowed to 
recover from anesthesia under heating lamps prior to return to the animal facility.  
Cyclosporine A will be administered to rats receiving human cells via gastral gavage to 
suppress rejection (6 mg/kg/day).  This is administered via gavage to reduce the amount of 
pain and physical trauma to the rat by daily IP injections.   
 
Stem Cell Culture and Maintenance 
Undifferentiated male hES cell colonies (grown on a layer of mouse endothelial 
fibroblasts (MEFs) in hES medium [20% KSR, DMEM/F12, 1% NEAA, 1% L-Glutamine, 
0.1mM BME, 4ng/mL FGF-2] in 3% O2 conditions) are collected under direct vision using 
a combination of collagenase IV digestion and mechanical disruption, to strip the colonies 
away from the underlying fibroblast feeder layer.  The colonies are allowed to repeatedly 
sediment and are washed three times, then triturated gently to give a single cell suspension.   
For studies with cells more defined than hES cells, a protocol is followed to differentiate 
hES cells in the CNS cells.  Undifferentiated male hES cell colonies grown on a feeder layer 




IV treatment.  This is repeated every four days up to p80.  To begin differentiation of the 
hES cells, they are detached from the MEF feeder layer using Accutase II treatment, and 
triturated to a single-cell suspension.  This is then transferred to matrigel-coated plates at a 
density of 105cells/cm2.  After 24 hours, the hES medium is replaced with NAA medium 
[DMEM/F12, 200µM transferin, 20µg/mL insulin, 20nM progesterone, 100µm putrescine, 
30mM sodium selenite, 10ng/mL FGF-2].  These cells are then allowed to grow for six days.  
On day eight, cells are detached using collagenase IV for 20 minutes, detached by gentle 
scraping.  Cells are transferred to bacterial Petri-dishes (3 x 3.5cm into 1 x 10cm) to form 
neurospheres in 15 days.  FGF-2 is added daily via the NAA medium.  After 15 days (day 
23), the neurospheres are placed onto tissue culture plates for 3 days.  After the three day 
outgrowth of neuro-precursor cells, they are triturated to a single cell suspension and 
transferred to polyornithine-coated plates (P0; 5x106 cells).  These neural progenitor cells are 
passaged after 3 days.   
 
Preparation of Implants 
PGS scaffolds are rinsed in an ethanol wash series (70%, 50%, and 25%) for 30 minutes 
each, followed by a 30 minute PBS rinse.  Scaffolds are then incubated in the culture 
medium overnight prior to seeding.  Following the injection of the cell suspension, the 
scaffolds are submerged in medium and incubated for 6 hours at 3% O2.  At this point the 
cells are resuspended by detachment from the MEF layer by collagenase IV treatment, 
washed 3 times and triturated gently into a single-cell suspension.   An aliquot is taken for 
counting.  The cells are suspended in liquid alginate at a density of 500,000 cells per 100µL, 
of which is then injected through the lumen of the PGS scaffold.  The scaffold is then 




 In order to compare the hES cells with the previous literature, the use of Schwann cells 
in this study is essential.  From the point at which the cells are suspended in alginate at the 
density of 500,000 cells per 100µL into the scaffolds, there will be scaffolds with no cells, 
hES cells, NPCs, and Schwann cells, with the varying conditions of with/without alginate, 
and 6% vs. 20% oxygen.  By comparing the findings with no cells and Schwann cells to that 
of the literature, it should be easily determined whether the stem cells or neural progenitor 
cells are enhancing regeneration or not.   
 
Scaffold Optimization 
Nerve regeneration and scaffold degradation will be observed every 10 days.  In tact 
scaffolds are explanted followed by a soak in calcium/barium-free solution to depolymerize 
the alginate, followed by a 0.25% trypsin treatment to remove any cellular material.  Volume 
is determined by submerging the scaffolds in mercury, measuring displacement.  The 
explants are then dried at 40ºC under vacuum (85mTorr) for 48h.  Optimization of scaffold 
size will depend on the experimental rate of nerve regeneration versus the rate of 
degradation of the scaffold.   
 
Tissue Processing for Histology 
The distal half of the sciatic nerve and proximal half will be separately analyzed with the 
lesion and scaffold in the distal half.  Continuity of the nerve will be noted at autopsy and 
photos of the gross morphology taken.  Nerve samples will be soaked in sterile saline, then 
fixed in periodate-lysine-paraformaldehyde (PLP) for 30 minutes, then stored in 10% 
sucrose.  The samples are dried in graded alcohols and embedded in paraffin.  The 
midsection, containing the lesion and scaffold will be sectioned in 1µm sections to quantify 




evaluate the persistence of inflammatory infiltrates and the number of Schwann cells.  
Sections will be prepared for histology using a cryomicrotome or by paraffin wax 
embedding.   
 
Histochemistry and Immunohistochemistry 
Because the cells implanted are human cells, even differentiated cells will express human 
alkaline phosphatase (hAP) and human IgG.  Schwann Cells are labeled and counted using 
Anti-S100β.  Comparing the Anti-hAP and Anti-IgG labeled cells with the Anti-S100β cells 
will indicate whether the cells are derived from the stem cells or the native tissue.  Tissue 
slides are fixed in 4% paraformaldehyde (PF) for 5 min and then labeled with the primary 
and secondary antibodies.  Nuclei are counterstained with DAPI154.   
To observe the general anatomy of the nerve, the tissue will be prepared using eosin and 
hematoxylin staining.  If preparations were embedded in paraffin wax, the wax is removed in 
2 changes of xylene, soaking 10 minutes each.  The samples are rehydrated in 100% ethanol 
twice for 5 minutes, and then briefly washed.  The sample is then stained in hematoxylin for 
8 minutes followed by a 5 minute wash in running water.  The stain is differentiated in 1% 
acid alcohol for 30 seconds, and then washed in running water for 30 seconds.  Samples are 
then added to a 0.2 ammonia water solution for 45 seconds followed by another 5 minute 
running water rinse.  They are then dipped in 95% ethanol 10 times before counterstaining 
in eosin Y solution for 45 seconds.  The sample is then dehydrated in 95% ethanol and 2 
changes of absolute ethanol for 5 minutes each.  This is finished with 2 changes of xylene 
for 5 minutes each and mounting with a xylene-based mounting medium.   
Preparation for SEM begins with immersion of the (paraffin removed) sample in 3% 




post-fixed in osmium tetroxide in buffer for 2 hours.  The tissue is dehydrated via a serial 
wash in ethanol starting with 50% in buffer up to 100% ethanol.  Each of the 6 washes is 30 
minutes.  Samples are dried in a critical point dryer and then transferred to an SEM sample 
holder.  This is then placed in the sputtering device where a heavy metal is sputtered over 
the entire sample under vacuum.  Once the sample is sputtered it can be placed in the SEM 
chamber, vacuum brought down, and then viewed.   
 
Molecular Biology 
The tissue of interest is collected, weighed, and homogenized in 3mL of PBS buffer per 
gram of tissue, maintaining 4°C throughout.  This is incubated for 30 minutes and 
transferred to microcentrifuge tubes.  This slurry then centrifuged at 400g for 10 minutes at 
4°C.  The supernatant is removed and discarded and tissue is washed again.  After the 
second wash, the supernatant is again removed and tissue is resuspended in 600µL lysis 
buffer per gram tissue, which contains a protease inhibitor cocktail.  The sample is gently 
vortexed and then placed on ice for a 30 minute incubation with occasional mixing.  The 
lysate is centrifuged at 10,000g for 15 minutes at 4°C.  The supernatant is collected and 
transferred to a clean tube.   
 50µL of Protein G slurry is transferred to an eppendorf tube along with 450µL of cold 
lysis Buffer.  The beads are centrifuged at 10,000g for 30 seconds and washed again with 
lysis buffer, and then finally resuspended in 50µL of lysis buffer.  This 50µL slurry of Protein 
G is added to 500µL of cell lysate in a new tube and incubated for 60 minutes.  The samples 
are then spun at 10,000g for 10 minutes at 4°C and the supernatants are collected, being 




 About 5-10µg of antibody for the target protein (NGF, EPO, BDNF, GDNF, etc.) is 
added to the pre-cleared lysate and incubated for an hour.  50µL of washed Protein G slurry 
in lysis buffer is then added and the sample is incubated for 1 hour at 4°C on a rotator.  The 
sample is centrifuged at 10,000g for 30 seconds and 4°C.  The supernatant is completely 
collected and the beads are washed 3-5 times with 500µL of lysis buffer.  After the last wash, 
the supernatant is aspirated followed by the addition of 50µL of Laemmli sample buffer to 
the bead pellet.  This is vortexed and heated to 90-100°C for 10 minutes.  The samples are 
again spun at 10,000g for 5 minutes and the supernatant is collected and loaded onto the 
SDS-polyacrylamide gel.  The protocol for running the SDS-PAGE will be per 
manufacturer.  The gel will be incubated in a blocking buffer (5% carnation dry milk in 
TBST) prior to exposure to the primary antibody, which will be incubated overnight.  The 
gel will be thoroughly washed before incubating in the secondary antibody.   
 
Figure 4:  Determination of SFI using ink to track the paw prints of rats before and after 





Aims and Procedure for Future Study 
 
 
In this chapter, I bring forward specific aims for potential continuation of this work.  
These are presented in the final chapter because none of the aims were fully completed, 
however, if future studies continue with this research, the following aims may set a guideline 
as to how to continue.  
Aim 1: Optimize the scaffolds to deliver embedded stem cells and 
provide mechanical support of the recovering nerve   
The working hypothesis is that physical and chemical properties affect the 
performance of the hydrogel and scaffold in vivo.  Physical parameters of the scaffold to be 
optimized include the pore size, porosity, and physical size of the scaffold itself.  The cross-
linking density controls the hydrophobicity of PGS, and thus the adsorption of various 
important ECM proteins.  The concentration of alginate will be adjusted to optimize the 
release of neural growth factors such as Epo, BDNF, GDNF, or NGF while the viscosity 
must be optimized for delivery into the porous scaffold.  This study will begin in vitro to 
optimize the seeding and implantation of the stem cells and Schwann cells followed by a 
further optimization in vivo, using data obtained as feedback for degradation rates and 
regeneration rate.  Success in vitro will be determined by maintenance of the stem cells and 
Schwann cells within the gel/scaffold in culture for 2 weeks.  The gel is broken down 
releasing the cells, which will then be quantified in number and viability.  If the cells are 
viable and still remain, then optimization of the scaffold in vivo will resume.  Success in vivo 




throughout the healing process and communication of the seeded cells with the 
endogenous system. 
Aim 2: Evaluate the ability of the scaffolds to reverse neuropathic pain 
induced by Chronic Constriction Injury  
The working hypothesis is that the human embryonic stem (hES) cell or neural 
progenitor cell (NPC)-seeded implants will better recover the chronic constriction injury 
(CCI) than Schwann cells or without cells by faster reducing the neuropathic pain.  A 
secondary hypothesis predicts that the implant will yield a minimal immune response, as 
well as have no significant effect on the sciatic nerve or behavior of the rats. Behavioral tests 
analyzing the rats’ responses to calibrated thermal and mechanical stimuli will be performed 
daily to quantify neuropathic pain.  Neuropathic pain will be confirmed with significant 
hypersensitivity to the stimuli.  Rats will be euthanized at different times from 0 day to 90 
days to observe the healing and degradation of the polymers.  The site of surgery will be 
examined pathologically, histologically, and by immunostaining following euthanization.  
Success will be defined by the recovery of behavioral function without neuropathic 
pain in correlation with appropriate physiology of the site of injury.  Furthermore, the 
suppression of teratoma formation is essential for the efficacy of this procedure.  Histology 
and immunochemistry will be used to determine the origin of the cells and tissues present in 
different regions of the lesion.   
 
Aim 3: Examine the recovery from neuropathic pain with scaffold 
implantation following Autologous Nerve Grafting 
My working hypothesis is that the implant seeded with hES or NPCs will better 
recover the potential neuropathic pain resulting from autologous nerve grafting than 




Behavioral tests will be performed daily to assess any neuropathic pain. Rats will be 
euthanized at different times for further analysis as performed in Aim 2.  The success of 
this aim will be shown with improved behavioral recovery as quantified by 
observation of the gait of rats post operatively as well as the recovery from 
neuropathic pain as demonstrated by the thermal and mechanical stimuli testing.   
 
Aim 4: Compare the neuroregenerative potential of young vs. aged rats 
It is known that there is a decline of regenerative potential of peripheral nerves with age.  
The working hypothesis of this aim is that the use of the optimized seeded scaffold will 
recover the aged rats in a time frame similar to the young rats.  This will be analyzed 
comparing young rats (<3mo.) with aged rats (>8mo.) performing the chronic constriction 
injuries and autografting techniques as in previous experiments. Results will be analyzed by 
functional recovery and presence of neuropathic pain.  Success will be based on the 
ability of the scaffolds to aid in complete recovery of aged rats in a time frame similar 
to the young rats.   
 
Aim 5: Compare the neuroregenerative potential of superoxide 
dismutase knockout rats   
Superoxide dismutase is directly related to the oxidative damage imposed on the cell, 
thus the working hypothesis is that the use of the optimized ES cell-seeded scaffold will 
provide an environment that induces an endogenous response that will recover the damaged 
nerve.  Rats that will be compared will include homozygous Sod1 (-/-) (Cu, Zn-SOD), 
heterozygous Sod2 (+/-) (Mn-SOD), and homozygous GPx1 (-/-).   Both injury models will 
be tested with the aforementioned varying conditions.  Results will be analyzed based on 




the creation of a model that can link the common growth factors, common aging 




The cumulative studies as described in these five aims both reflect and penetrate into the 
topics initially discussed:  the problems of neuropathic pain, a method to potentially reduce 
or reverse neuropathic pain, the notion that neural regeneration declines with age, and the 
capacity of a cell-infused implant to aid in neural regeneration and reconstruction in both 
cases of injured and severed nerves.   
 Aim 1 explores the capacity of the implant to guide nerve repair using different types of 
cells, NPCs, hES cells, and Schwann cells to repair the nerve in vivo.  The ultimate goal of 
this aim will be based on feedback and alteration of the physical properties of the biomaterial 
scaffold as well as the concentration of cells delivered to the site of injury.  Schwann cells are 
included to compare with existing studies that have only used Schwann cells in NGCs102, 103, 
109, 115.   
 While there is still some controversy in whether these experiments using a transected 
sciatic nerve from rat is even significant, a more established model is used to explore the 
effects on neuropathic pain in Aim 2.  Furthermore, the incidence of chronic neuropathic 
pain is much higher in the CCI model than in nerve transection.   Aim 2 follows the 
standard protocols of Bennett and Xie38 to explore the different symptoms of neuropathic 
pain, and then examines these symptoms following implantation of the seeded scaffold.  
This Aim more clearly examines the aspect of pain whereas Aim 3 is more focused on the 




 Like Aim 2, Aim 3 utilizes the optimized scaffold from Aim 1 and applies it to the sciatic 
transection model, observing the recovery from this injury.  This is compared both to natural 
recovery as well as with the standard medical procedure in such cases, which is autologous 
nerve grafting.  Similar to the tests in Aim 2, the rats in this study will be examined for 
neuropathic pain and subsequent recovery.  As mentioned above, the incidence of pain is 
less with neural transection than with CCI.  Furthermore, this study should be continued 
with a larger animal such as a rabbit, where a full 15mm section of the sciatic nerve can be 
removed and watched for recovery as there is some controversy as to whether 10-12mm 
sections in rats are long enough for significant results.   
 Aims 4 and 5 both explore the process of aging.  With aging, it is known that both 
recovery of function and loss of pain come at a much slower rate if at all.  Aim 4 compares 
the studies explored in Aims 2 and 3 amongst young and old rats to confirm this reduced 
healing potential as well as to observe how the implant can affect the rates of recovery and 
reversal of neuropathic pain.  Aim 5 explores deeper into one potential cause of cellular 
aging, free oxygen radical damage. 
 In order to explore how oxygen radical damage affects the body, of knockout rats for the 
enzymes that reduce the free oxygen radicals will be used to simulate aging.  Characteristics 
of these rats will be documented before the procedures employed in Aims 2 and 3 will again 
be used.  Once accomplished, the data from Aim 5 will be compared to that of Aim 4 to 
cross-examine the model for aging with actual aged rats. 
 All of the Aims, while separate, all drive to answer a set of questions posed in the 
Introduction.  Aim 1 is the driving step in this research, and provides the optimized scaffold 
for delivery of the cells that are hypothesized to aid in the neuroregenerative process.  Aims 




the data of regenerative potential, functional recovery, as well as recovery from neuropathic 
pain.  Aims 4 and 5 push beyond the initial studies and examine how aging negatively affects 
neural regeneration and whether oxidative stress is the cause of this and whether this implant 
can restore the lost or lagging neural potential, and drive even an elderly nerve to full 
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